Vaxcyte · 5 hours ago
Associate Scientist II, Analytical Development, Raw Materials (contract)
Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from bacterial diseases. They are seeking an energetic and talented individual to join their analytical development team, focusing on method development, sample testing, and data analysis.
BiopharmaBiotechnologyHealth Care
Responsibilities
Assist in analytical method development of new assays
Perform analytical testing, data analysis and present in team meetings
Maintain thorough and accurate records of laboratory work
Support daily lab operations, sample inventory and sample shipment
Author analytical documents including but not limited to test method, protocols, and reports
Qualification
Required
BS in Chemistry, Analytical Chemistry preferred, Organic / Biochemistry considered, with 2+ years of relevant industry experience, or MS with 1+ years of experience. Other combinations of education and/or experience may be considered
Experience in chemical and biological assays such as colorimetric/ fluorometric microplate assays, PCR/qPCR, HPLC, CE, UV-Vis, ELISA and LC-MS
Understanding of basic principles of analytical method development/ validation/ qualification concepts
Attention to detail and excellent skills in record keeping/documentation
Strong interpersonal skills and ability to communicate effectively both verbally and in written formats
This position is a lab-based role and requires onsite presence
Company
Vaxcyte
Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
H1B Sponsorship
Vaxcyte has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (14)
2024 (7)
2023 (5)
2022 (7)
2021 (2)
Funding
Current Stage
Public CompanyTotal Funding
$3.85BKey Investors
CARB-XTPG GrowthAbingworth
2024-09-04Post Ipo Equity· $1.5B
2024-01-30Post Ipo Equity· $862.5M
2023-04-19Post Ipo Equity· $500M
Leadership Team
Recent News
2025-12-09
Company data provided by crunchbase